Moody Lynn & Lieberson, LLC Biogen Inc. Transaction History

Moody Lynn & Lieberson, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 02, 2023	SELL	$256.56 - $292.34 $37,201 - $42,389	-145 Reduced 2.4%	5,890 $1.64 Million
Q4 2022 Feb 01, 2023	BUY	$252.44 - $306.72 $1.52 Million - $1.85 Million	6,035 New	6,035 $1.67 Million
Q1 2019 Apr 23, 2019	SELL	$216.71 - $338.96 $3.48 Million - $5.45 Million	-16,075 Closed	0 $0
Q4 2018 Jan 29, 2019	SELL	$278.5 - $352.75 $5.46 Million - $6.92 Million	-19,618 Reduced 54.96%	16,075 $4.84 Million
Q3 2018 Oct 29, 2018	BUY	$293.51 - $383.83 $3.87 Million - $5.07 Million	13,197 Added 58.66%	35,693 $12.6 Million
Q2 2018 Jul 24, 2018	BUY	$257.52 - $306.91 $363,618 - $433,356	1,412 Added 6.7%	22,496 $6.53 Million
Q1 2018 Apr 27, 2018	SELL	$260.13 - $367.91 $3.93 Million - $5.56 Million	-15,118 Reduced 41.76%	21,084 $5.77 Million
Q4 2017 Feb 02, 2018	BUY	$307.64 - $344.58 $11.1 Million - $12.5 Million	36,202	36,202 $12.8 Million

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Moody Lynn & Lieberson, LLC, based on Form 13F filings with the SEC.

Stay updated on Moody Lynn & Lieberson, LLC with notifications on news.